Showing results (1931-1940 of 2,093) with videos related to

Sort By:
Pageof 210
Molecular Cancer Therapeutics|July 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsMichael S Gordon, John Nemunaitis, Minal Barve, et al.
NPJ Genomic Medicine|December 22, 2017
Precision Military Medicine: Conducting a multi-site clinical utility study of genomic and lifestyle risk factors in the United States Air ForceSusan K Delaney, Ruth Brenner, Tara J Schmidlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
British Journal of Clinical Pharmacology|December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumoursNoelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 13, 2026
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expressionJessica L Neil, Naheema S Gordon, Anshita Goel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 27, 2015
Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected PatientsDaniel F Weisberg, Kirsha S Gordon, Declan T Barry, et al.
Open Forum Infectious Diseases|June 1, 2026
Impact of SARS-CoV-2 Breakthrough Infection on Short-Term CD4 Count Among Adults With HIV in the United States From 2020 to 2022Lincoln Hopkins, Elizabeth Humes, Kirsha S Gordon, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
A global map for introgressed structural variation and selection in humansPingHsun Hsieh, Natthapon Soisangwan, David S Gordon, et al.
Substance Abuse|January 24, 2012
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationersDonna M Coviello, James W Cornish, Kevin G Lynch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancerMichael S Gordon, Francisco Robert, Daniela Matei, et al.
Pageof 210